AXSM
Overvalued by 81% based on the discounted cash flow analysis.
Market cap | $5.18 Billion |
---|---|
Enterprise Value | $5.09 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-5.99 |
Beta | 0.45 |
Outstanding Shares | 48,871,163 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -18.47 |
---|---|
PEG | 141.15 |
Price to Sales | 13.52 |
Price to Book Ratio | 108.14 |
Enterprise Value to Revenue | 11.77 |
Enterprise Value to EBIT | -18.63 |
Enterprise Value to Net Income | -19 |
Total Debt to Enterprise | 0.04 |
Debt to Equity | 3.94 |
No data
No data
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...